Proxy Statement Shows Danaher Faced Competition In Bid To Buy Cepheid

In a note released Monday, Barclays said about four companies sought to bid for Cepheid (NASDAQ: CPHD). This follows a review of the proxy statement released by the company last Friday regarding its announced acquisition by Danaher Corporation (NYSE: DHR) for $4 billion or $53 per share.

Jack Meehan, an analyst at the firm, noted that one of the bidders' bid was merely $0.50 less than Danaher's bid. Cepheid, according to analyst, preferred Danaher due to less regulatory risk and the modestly better offer price.

Related Link: Cepheid Reports Expansion Of Binary Toxin Gene Reporting, Added To Xpert C. Difficile Portfolio

Comparing Cepheid's proxy statement with Alere Inc (NYSE: ALR)'s statement, Barclays noted that the early bidding process for both assets reveal interesting insights. Apart from the number of companies in the fray, the firm said the proxy included Cepheid management's projections on the business, showing double-digit revenue growth annually through 2025.

Barclays also noted that Cepheid is required to pay a termination fee of $131 million in cash if the deal is terminated and that the shareholders of Cepheid will vote on three proposals recommended by the board at the general meeting.

At time of writing, Danaher shares were down 1.2 percent at $76.66, and Cepheid was modestly up (+0.27 percent) at $52.64.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!